12:00 AM
Nov 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TM38837: Phase I data

A double-blind, placebo-controlled, crossover, Dutch Phase I trial in 24 healthy volunteers showed that a single 500 mg dose of oral TM38837 attenuated the CNS effects of...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >